CN108714207A - 益气通络膏 - Google Patents
益气通络膏 Download PDFInfo
- Publication number
- CN108714207A CN108714207A CN201810549762.5A CN201810549762A CN108714207A CN 108714207 A CN108714207 A CN 108714207A CN 201810549762 A CN201810549762 A CN 201810549762A CN 108714207 A CN108714207 A CN 108714207A
- Authority
- CN
- China
- Prior art keywords
- parts
- activating
- skin
- collateral
- collateral cream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003213 activating effect Effects 0.000 title claims abstract description 43
- 239000006071 cream Substances 0.000 title claims abstract description 41
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 51
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 30
- 102000008186 Collagen Human genes 0.000 claims abstract description 18
- 108010035532 Collagen Proteins 0.000 claims abstract description 18
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims abstract description 18
- 229920001436 collagen Polymers 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- VLDFMKOUUQYFGF-UHFFFAOYSA-N 4-(butoxymethyl)-2-methoxyphenol Chemical compound CCCCOCC1=CC=C(O)C(OC)=C1 VLDFMKOUUQYFGF-UHFFFAOYSA-N 0.000 claims abstract description 17
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 17
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 17
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 17
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960001631 carbomer Drugs 0.000 claims abstract description 17
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 17
- 235000011187 glycerol Nutrition 0.000 claims abstract description 17
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 17
- 229930014456 matrine Natural products 0.000 claims abstract description 17
- 229940078465 vanillyl butyl ether Drugs 0.000 claims abstract description 17
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 16
- 229960005323 phenoxyethanol Drugs 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 15
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 15
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 15
- 150000008065 acid anhydrides Chemical class 0.000 claims abstract description 15
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 15
- 229940041616 menthol Drugs 0.000 claims abstract description 15
- 229920006389 polyphenyl polymer Polymers 0.000 claims abstract description 15
- 229920005573 silicon-containing polymer Polymers 0.000 claims abstract description 15
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 15
- 239000011734 sodium Substances 0.000 claims abstract description 15
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940093633 tricaprin Drugs 0.000 claims abstract description 15
- 229940015060 c18-c21 alkane Drugs 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 5
- 235000019441 ethanol Nutrition 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 2
- 229960003993 chlorphenesin Drugs 0.000 claims description 2
- 229960005188 collagen Drugs 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims 1
- 241000732800 Cymbidium Species 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims 1
- 230000003020 moisturizing effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 abstract description 16
- 239000003053 toxin Substances 0.000 abstract description 13
- 231100000765 toxin Toxicity 0.000 abstract description 13
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 239000000047 product Substances 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 3
- 239000002158 endotoxin Substances 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 230000035764 nutrition Effects 0.000 abstract description 2
- 238000007920 subcutaneous administration Methods 0.000 abstract description 2
- 235000013619 trace mineral Nutrition 0.000 abstract description 2
- 239000011573 trace mineral Substances 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 210000000707 wrist Anatomy 0.000 description 4
- 235000016257 Mentha pulegium Nutrition 0.000 description 3
- 244000246386 Mentha pulegium Species 0.000 description 3
- 235000004357 Mentha x piperita Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000001050 hortel pimenta Nutrition 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 235000007421 Mentha citrata Nutrition 0.000 description 1
- 244000007703 Mentha citrata Species 0.000 description 1
- 235000008660 Mentha x piperita subsp citrata Nutrition 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000009321 antitumor A Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229940105902 mint extract Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000447 pesticide residue Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- -1 poly- Benzene olefin Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Inorganic Chemistry (AREA)
Abstract
本发明提供一种益气通络膏,由下述质量组份配比的原料制成的:水65~75份;卡波姆0.1~0.5份;三癸精5~7份;丙二醇5~7份;甘油5~7份;聚二甲基硅氧烷2~4份;水解胶原1~3份;香兰基丁基醚0.5~2份;薄荷醇0.5~2份;甘草酸二钾0.5~1.5份;苦参碱0.5~1.5份;三乙醇胺0.1~1份;苯氧乙醇0.1~0.5份;聚苯酐醚0.05~0.15份;香精0.05~0.15份;聚苯烯酸钠,C18—C21烷和十三烷醇聚醚—6中的一种或多种:0.1~1份。本发明所得产品可用于通络、修复、清除色斑,能彻底排除肌肤内毒素和皮下污垢;具有修护、营养、激活细胞活力的功能,给予因毒素受损肌肤温馨细致的关怀,补充肌肤所急需之微量元素和营养成分;真正的从基础护肤,让肌肤新陈代谢重回正确轨道,彻底告别毒素摧残的肌肤,肌肤恢复嫩白、细腻和弹力。
Description
技术领域
本发明涉及一种膏药制剂,具体涉及一种益气通络膏。
背景技术
现代人生活节奏快,工作压力大,相当一部分人群生活不规律、饮食不均衡、电脑辐射、化学物、环境污染、长期大量服用各种抗生素等药物;此外还有紫外线、污染物质等原因造成的“毒素”时刻侵浊人体,一部分人处于亚健康状态。根据相关研究资料表明:毒素总体可分为“外来之毒”和“内生之毒”两大类,外毒指来源于人体之外的,如大气污染、水污染、农药残留、汽车尾气等有害身体健康的致病物质;内毒指的是机体在新陈代谢后产生的各种废弃物,如果这些毒素在体内积存太久,长时间得不到清除,还会加速人体老化、记忆力衰退、疲劳、面色灰黄、便秘、痔疮和内分泌失调等不适之症。随着人们生活水平的提高,越来越认识到排毒已经成为现代人美容、保健、养生的一种时尚潮流。着力寻求以《皇帝内经》的经络学说、脏腑学说、阴阳平衡的中医理论为主要基础依据,以杀毒、排毒、祛风凉血、养血舒肝、理气解郁、益气固表、舒风祛邪为原则,促进微循环,提高人体免疫功能,调节体内各器官相互平衡为重点,及对传统中医的理解结合现代科技而诞生的一种安全、有效、绿色的保养方法。
为此需要提供一种排除体内风寒湿酸毒;并再通过三补:补肾元气、补氧气和补充头部组织细胞结构能量所需要的营养物质,达到足底“涌泉穴,经络从头到足都通畅了,百病自然消”的健康状态的技术方案。
发明内容
为了达到益气通络健康的目的,本发明制得产品通过冷却、雾化、纳米化才有非常强的渗透能力,通过皮肤直达患处,进行消炎、止痛、通络、修复受损细胞。本发明提出一种益气通络膏。
为了达到上述目的,本发明提供了采用下述技术方案:
一种益气通络膏,由下述质量组份配比的原料制成的:水65~75份;卡波姆0.1~0.5份;三癸精5~7份;丙二醇5~7份;甘油5~7份;聚二甲基硅氧烷2~4份;水解胶原1~3份;香兰基丁基醚0.5~2份;薄荷醇0.5~2份;甘草酸二钾0.5~1.5份;苦参碱0.5~1.5份;三乙醇胺0.1~1份;苯氧乙醇0.1~0.5份;聚苯酐醚0.05~0.15份;香精0.05~0.15份;聚苯烯酸钠,C18—C21烷和十三烷醇聚醚—6中的一种或多种:0.1~1份。
一种益气通络膏的第一优选方案,原料的质量配比是:水68~72份;卡波姆0.2~0.3份;三癸精5.5~6.5份;丙二醇5~6份;甘油5~6份;聚二甲基硅氧烷2.5~3.5份;水解胶原1.5~2.5份;香兰基丁基醚0.8~1.5份;薄荷醇0.8~1.5份;甘草酸二钾0.8~1.2份;苦参碱0.8~1.2份;三乙醇胺0.2~0.5份;苯氧乙醇0.1~0.3份;聚苯酐醚0.08~0.12份;香精0.08~0.12份;聚苯烯酸钠,C18—C21烷和十三烷醇聚醚—6中的一种或多种:0.2~0.5份。
一种益气通络膏的第二优选方案,原料的质量配比是:水70份;卡波姆0.3份;三癸精5.5份;丙二醇5份;甘油6份;聚二甲基硅氧烷3.5份;水解胶原1.5份;香兰基丁基醚1份;薄荷醇1.5份;甘草酸二钾0.8份;苦参碱1.2份;三乙醇胺0.2份;苯氧乙醇0.3份;聚苯酐醚0.12份;香精0.12份;聚苯烯酸钠0.5份。
一种益气通络膏的第三优选方案,原料的质量配比是:水71份;卡波姆0.2份;三癸精6份;丙二醇6份;甘油5份;聚二甲基硅氧烷3份;水解胶原2份;香兰基丁基醚1.2份;薄荷醇1.2份;甘草酸二钾1份;苦参碱1份;三乙醇胺0.4份;苯氧乙醇0.2份;聚苯酐醚0.1份;香精0.1份;聚苯烯酸钠0.1份,C18—C21烷:0.1份,十三烷醇聚醚—6 0.1份。
一种益气通络膏的第四优选方案,卡波姆,聚苯烯酸钠,C18—C21烷和十三烷醇聚醚—6为增稠剂。
一种益气通络膏的第五优选方案,三癸精和聚二甲基硅氧烷为润肤剂。
一种益气通络膏的第六优选方案,丙二醇和甘油为保湿剂。
一种益气通络膏的第七优选方案,水解胶原,香兰基丁基醚,薄荷醇,甘草酸二钾和苦参碱为调理剂。
一种益气通络膏的第八优选方案,三乙醇胺为中和剂。
一种益气通络膏的第九优选方案,苯氧乙醇和氯苯甘醚为防腐剂。
与最接近的现有技术相比,本发明提供的技术方案具有以下优异效果:
1)“深层清理、彻底排毒”——通络排毒、修复、清除色斑,彻底排除肌肤内毒素和皮下污垢;
2)“完美修护、温柔呵护”——修护、营养、激活细胞活力,给予因毒素受损肌肤温馨细致的关怀,补充肌肤所急需之微量元素和营养成分;真正的从基础护肤,让肌肤新陈代谢重回正确轨道,彻底告别毒素摧残的肌肤,肌肤恢复嫩白、细腻和弹力。
具体实施方式
下面结合具体实施例作进一步详细说明,对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明制得的产品可用于:排毒、强身、健体保养、前列腺保养、痹症保养、糖尿病保养、脾胃保养、睡眠保养、抑郁症保养、塑身保养、经络养肺、养心、养足、舒经通络、活血化瘀、消除疲劳、镇痛、调理跌打损伤、肩周炎、关节炎、痔疮、腰肌劳损、皮肤干裂、肌肉痛、头痛、偏头疼以及身体亚健康症状。平衡油脂分泌、排除毒素和多余水分,收缩毛孔,使肌肤自然收紧、提升。强化肌肤机能,让您的肌肤充满弹性和健康光泽。
使用方法:用于身体刮拭,亦可取适量涂抹于所需部位,打圈按摩直至吸收,一日多次效果更佳。结合汗蒸效果更佳。
实施例1
益气通络膏由下述质量组份配比的原料制成的:水65份;卡波姆0.1份;三癸精5份;丙二醇5份;甘油5份;聚二甲基硅氧烷2份;水解胶原1份;香兰基丁基醚0.5份;薄荷醇0.5份;甘草酸二钾0.5份;苦参碱0.5份;三乙醇胺0.1份;苯氧乙醇0.1份;聚苯酐醚0.05份;香精0.05份;十三烷醇聚醚—6 0.1份。
实施例2
益气通络膏由下述质量组份配比的原料制成的:水75份;卡波姆0.5份;三癸精7份;丙二醇7份;甘油7份;聚二甲基硅氧烷4份;水解胶原3份;香兰基丁基醚2份;薄荷醇2份;甘草酸二钾1.5份;苦参碱1.5份;三乙醇胺1份;苯氧乙醇0.5份;聚苯酐醚0.15份;香精0.15份;聚苯烯酸钠0.5份;C18—C21烷0.5份。
实施例3
益气通络膏由下述质量组份配比的原料制成的:水68份;卡波姆0.2份;三癸精5.5份;丙二醇5份;甘油5份;聚二甲基硅氧烷2.5份;水解胶原1.5份;香兰基丁基醚0.8份;薄荷醇0.8份;甘草酸二钾0.8份;苦参碱0.8份;三乙醇胺0.2份;苯氧乙醇0.1份;聚苯酐醚0.08份;香精0.08份;C18—C21烷0.1份;十三烷醇聚醚—6 0.1份。
实施例4
益气通络膏由下述质量组份配比的原料制成的:水72份;卡波姆0.3份;三癸精6.5份;丙二醇6份;甘油6份;聚二甲基硅氧烷3.5份;水解胶原2.5份;香兰基丁基醚1.5份;薄荷醇1.5份;甘草酸二钾1.2份;苦参碱1.2份;三乙醇胺0.5份;苯氧乙醇0.3份;聚苯酐醚0.12份;香精0.12份;聚苯烯酸钠0.25;十三烷醇聚醚—6 0.25份。
实施例5
益气通络膏由下述质量组份配比的原料制成的:水70份;卡波姆0.3份;三癸精5.5份;丙二醇5份;甘油6份;聚二甲基硅氧烷3.5份;水解胶原1.5份;香兰基丁基醚1份;薄荷醇1.5份;甘草酸二钾0.8份;苦参碱1.2份;三乙醇胺0.2份;苯氧乙醇0.3份;聚苯酐醚0.12份;香精0.12份;聚苯烯酸钠0.5份。
实施例6
益气通络膏由下述质量组份配比的原料制成的:水71份;卡波姆0.2份;三癸精6份;丙二醇6份;甘油5份;聚二甲基硅氧烷3份;水解胶原2份;香兰基丁基醚1.2份;薄荷醇1.2份;甘草酸二钾1份;苦参碱1份;三乙醇胺0.4份;苯氧乙醇0.2份;聚苯酐醚0.1份;香精0.1份;聚苯烯酸钠0.1份,C18—C21烷:0.1份,十三烷醇聚醚—6 0.1份。
水解胶原适合人群:
1、由于工作劳累,睡眠不足形成的皮肤晦暗无光、发黄、皮肤弹性差等皮肤衰老的不良症状。
2、由于年龄、太阳辐射因素引起的皮肤松弛、下垂、皱纹、干燥等皮肤衰老现象。
3、由于体内异常黑色素分泌旺盛,大量沉积皮肤表面,肌肤不能及时代谢出异常黑色素,形成各种色斑。如色斑,黄褐斑、雀斑、早期老年斑等。
4、由于长期户外活动及皮肤保养不当使肤质受到损伤,过早出现细纹,皮肤干燥、脱皮、红肿、毛孔粗大等不良症状。
5、由于内分泌功能紊乱,皮肤肤质差、皮肤发油、发暗,易长青春痘留下的色印、色素沉着等。
6、由于生活无规律,吸烟等因素,造成的黑眼圈,眼袋等问题。
7.、长期电脑旁工作,电脑辐射造成脱发,内分泌紊乱问题。
香兰基丁基醚的特点:
1、常温下为黄色透明液体,不溶于水,溶于乙醇和油脂中;
2、对皮肤具有热感效果,热感持久;
3、将少量热感剂添加到凉感剂中,可提高皮肤的凉感效果;
4、与辣椒素相比,刺激性低,性价比高。
薄荷醇:在医药上用作刺激药,作用于皮肤或粘膜,有清凉止痒作用;内服可用于头痛及鼻、咽、喉炎症等。
甘草酸二钾:
医药工业:用于镇咳祛痰、胃溃疡、急慢性胃炎、湿疹、皮肤瘙痒、肝炎、高血脂症、结膜炎,并用于治疗癌症及防治艾滋病。
妆品工业:在化妆品中有广泛的配伍性,常与其它活性剂共用,可加速皮肤对它们的吸收而增效,可用于防晒、协助美白、止痒、调节皮脂、生发护发等。可防止皮肤炎、皮肤干燥、日晒、皮疹、润喉等。祛斑剂,抗过敏剂。用于抗过敏、防晒、护肤水、祛斑霜膏、乳液等。
苦参碱:主要功用具有清热、利尿、杀虫、祛湿等功效,同时还具有抗病毒、抗肿瘤抗过敏等多种作用。
根据上述实施例1-6的原料配比制备益气通络膏,患者使用案例如下表:
| 实施例1 | 实施例2 | 实施例3 | 实施例4 | 实施例5 | 实施例6 | |
| 患者 | 1 | 2 | 3 | 4 | 5 | 6 |
具体患者案例使用益气通络膏情况如下:
患者案例1:赵先生48岁广西人
症状:因多种原因造成右侧肩周受损,活动受限,疼痛无力,握拳都困难,有时日轻夜重,甚至半夜被疼醒无法入睡,尤其在工作中,右侧手臂上举、外展、内收、后伸、摸背等动作均会明显受限,疼痛钻心,右边手臂有明显萎缩现象。
治疗效果:脚底用益气通络膏第21天,所有症状全部消失,关节炎活动自如,而且睡眠、胃口、精神都很好。
患者案例1:杨女士51岁广西人
症状:时常头晕、头痛、颈部疼痛,两肩僵硬,手指麻木和乏力,失眠。
治疗效果:做益气通络保养半个月后,症状消失,脸色红润,精神状态好。
患者案例2:王先生65岁珠海人
症状:腰椎骨年轻时受过伤,后又发现骨质增生,平时稍不留意老伤容易复发,短则半小时,长则个把月方能恢复。
治疗效果:在要不疼痛处涂抹,然后用保鲜膜包住,中午、晚上各抹3次,每次间隔20分钟,僵硬的腰肌当天松软,3天后恢复如初。
患者案例3:施女士62岁珠海人
症状:煮饭时被高温汽烫到左手掌,红肿辣痛。
使用效果:马上使用益气通络膏涂抹手掌,间隔5分钟左右再抹,共抹5次,很快红肿开始消退,痛感减轻直至消失,恢复正常,未见皮肤起皱和生水泡。
患者案例4:穆女士57岁河南人
症状:患类风湿20多年,高血压10多年,脑血栓2年。
使用效果:做了五次通络强身健体保养,关节痛明显减轻。益气通络膏涂抹手心和脚心,三个月后血压正常,脑血栓后遗症消失。
患者案例5:郭女士27岁四川人
症状:痛经。
使用效果:四月做卵巢经络保养三次并做局部加强,益气通络膏,用足浴蒸桶。三次后来月经,肚子不痛了。
患者案例6:黄小姐30岁深圳人
症状:生产后双手腕肿痛,诊断为腱鞘炎。
使用效果:两天做一次通络强身健体保养,手腕处白天晚上均抹益气通络膏;一周后双腕肿痛消失,后又坚持在双腕处抹益气通络膏一个月,肿痛症状完全消失。
以上实施例仅用以说明本发明的技术方案而非对其进行限制,所属领域的普通技术人员应当理解,参照上述实施例可以对本发明的具体实施方式进行修改或者等同替换,这些未脱离本发明精神和范围的任何修改或者等同替换均在申请待批的权利要求保护范围之内。
Claims (10)
1.一种益气通络膏,其特征在于,所述益气通络膏由下述质量组份配比的原料制成的:水65~75份;卡波姆0.1~0.5份;三癸精5~7份;丙二醇5~7份;甘油5~7份;聚二甲基硅氧烷2~4份;水解胶原1~3份;香兰基丁基醚0.5~2份;薄荷醇0.5~2份;甘草酸二钾0.5~1.5份;苦参碱0.5~1.5份;三乙醇胺0.1~1份;苯氧乙醇0.1~0.5份;聚苯酐醚0.05~0.15份;香精0.05~0.15份;聚苯烯酸钠,C18—C21烷和十三烷醇聚醚—6中的一种或多种:0.1~1份。
2.根据权利要求1所述的一种益气通络膏,其特征在于,所述原料的质量配比是:水68~72份;卡波姆0.2~0.3份;三癸精5.5~6.5份;丙二醇5~6份;甘油5~6份;聚二甲基硅氧烷2.5~3.5份;水解胶原1.5~2.5份;香兰基丁基醚0.8~1.5份;薄荷醇0.8~1.5份;甘草酸二钾0.8~1.2份;苦参碱0.8~1.2份;三乙醇胺0.2~0.5份;苯氧乙醇0.1~0.3份;聚苯酐醚0.08~0.12份;香精0.08~0.12份;聚苯烯酸钠,C18—C21烷和十三烷醇聚醚—6中的一种或多种:0.2~0.5份。
3.根据权利要求1所述的一种益气通络膏,其特征在于,所述原料的质量配比是:水70份;卡波姆0.3份;三癸精5.5份;丙二醇5份;甘油6份;聚二甲基硅氧烷3.5份;水解胶原1.5份;香兰基丁基醚1份;薄荷醇1.5份;甘草酸二钾0.8份;苦参碱1.2份;三乙醇胺0.2份;苯氧乙醇0.3份;聚苯酐醚0.12份;香精0.12份;聚苯烯酸钠0.5份。
4.根据权利要求1所述的一种益气通络膏,其特征在于,所述原料的质量配比是:水71份;卡波姆0.2份;三癸精6份;丙二醇6份;甘油5份;聚二甲基硅氧烷3份;水解胶原2份;香兰基丁基醚1.2份;薄荷醇1.2份;甘草酸二钾1份;苦参碱1份;三乙醇胺0.4份;苯氧乙醇0.2份;聚苯酐醚0.1份;香精0.1份;聚苯烯酸钠0.1份,C18—C21烷:0.1份,十三烷醇聚醚—60.1份。
5.根据权利要求1所述的一种益气通络膏,其特征在于,所述卡波姆,聚苯烯酸钠,C18—C21烷和十三烷醇聚醚—6均为增稠剂。
6.根据权利要求1所述的一种益气通络膏,其特征在于,所述三癸精和聚二甲基硅氧烷均为润肤剂。
7.根据权利要求1所述的一种益气通络膏,其特征在于,所述丙二醇和甘油均为保湿剂。
8.根据权利要求1所述的一种益气通络膏,其特征在于,所述水解胶原,香兰基丁基醚,薄荷醇,甘草酸二钾和苦参碱均为调理剂。
9.根据权利要求1所述的一种益气通络膏,其特征在于,所述三乙醇胺为中和剂。
10.根据权利要求1所述的一种益气通络膏,其特征在于,所述苯氧乙醇和氯苯甘醚均为防腐剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810549762.5A CN108714207A (zh) | 2018-05-31 | 2018-05-31 | 益气通络膏 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810549762.5A CN108714207A (zh) | 2018-05-31 | 2018-05-31 | 益气通络膏 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108714207A true CN108714207A (zh) | 2018-10-30 |
Family
ID=63912574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810549762.5A Pending CN108714207A (zh) | 2018-05-31 | 2018-05-31 | 益气通络膏 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108714207A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109568329A (zh) * | 2018-12-07 | 2019-04-05 | 中国人民解放军第二军医大学 | 甘草酸及其药学上可接受的盐在制备抗抑郁药物中的应用 |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370697A (zh) * | 2011-10-27 | 2012-03-14 | 吴克 | 一种用于急慢性湿疹、皮炎的护理霜 |
| CN102525859A (zh) * | 2012-02-03 | 2012-07-04 | 广州雅纯化妆品制造有限公司 | 一种羧甲基酵母葡聚糖乳液及其制备方法和应用 |
| CN103386011A (zh) * | 2012-05-11 | 2013-11-13 | 贵州顶效开发区布医坊民族特色用品有限公司 | 一种排毒贴 |
| CN103705426A (zh) * | 2014-01-07 | 2014-04-09 | 梁云生 | 一种修复皮肤屏障功能抗过敏保湿组合物及其外用制剂 |
| CN104546650A (zh) * | 2014-12-26 | 2015-04-29 | 广东洁新生物科技有限公司 | 一种紧致肌肤的面膜及其制作方法 |
| CN104918662A (zh) * | 2013-01-11 | 2015-09-16 | 宝洁公司 | 包含可再生资源的润肤剂和固定剂的洗剂 |
| CN105250158A (zh) * | 2015-07-28 | 2016-01-20 | 朱耀灯 | 一种润体乳及其制备方法 |
| CN105267134A (zh) * | 2014-12-12 | 2016-01-27 | 广州宝珂日用品有限公司 | 含花蜜、鳄梨油的36小时保湿霜及其制备方法 |
| CN106726920A (zh) * | 2016-12-16 | 2017-05-31 | 广州市科能化妆品科研有限公司 | 一种保湿化妆水及其制备方法 |
| CN107007509A (zh) * | 2017-05-19 | 2017-08-04 | 广州蜜妆生物科技有限公司 | 一种平衡修护面霜 |
| CN107184499A (zh) * | 2017-04-12 | 2017-09-22 | 广州环亚化妆品科技有限公司 | 一种天然植物来源的长效保湿乳液面膜组合物及其制备方法 |
| CN107811889A (zh) * | 2017-11-06 | 2018-03-20 | 诺斯贝尔化妆品股份有限公司 | 一种具有热感的无矿油暖手霜 |
-
2018
- 2018-05-31 CN CN201810549762.5A patent/CN108714207A/zh active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102370697A (zh) * | 2011-10-27 | 2012-03-14 | 吴克 | 一种用于急慢性湿疹、皮炎的护理霜 |
| CN102525859A (zh) * | 2012-02-03 | 2012-07-04 | 广州雅纯化妆品制造有限公司 | 一种羧甲基酵母葡聚糖乳液及其制备方法和应用 |
| CN103386011A (zh) * | 2012-05-11 | 2013-11-13 | 贵州顶效开发区布医坊民族特色用品有限公司 | 一种排毒贴 |
| CN104918662A (zh) * | 2013-01-11 | 2015-09-16 | 宝洁公司 | 包含可再生资源的润肤剂和固定剂的洗剂 |
| CN103705426A (zh) * | 2014-01-07 | 2014-04-09 | 梁云生 | 一种修复皮肤屏障功能抗过敏保湿组合物及其外用制剂 |
| CN105267134A (zh) * | 2014-12-12 | 2016-01-27 | 广州宝珂日用品有限公司 | 含花蜜、鳄梨油的36小时保湿霜及其制备方法 |
| CN104546650A (zh) * | 2014-12-26 | 2015-04-29 | 广东洁新生物科技有限公司 | 一种紧致肌肤的面膜及其制作方法 |
| CN105250158A (zh) * | 2015-07-28 | 2016-01-20 | 朱耀灯 | 一种润体乳及其制备方法 |
| CN106726920A (zh) * | 2016-12-16 | 2017-05-31 | 广州市科能化妆品科研有限公司 | 一种保湿化妆水及其制备方法 |
| CN107184499A (zh) * | 2017-04-12 | 2017-09-22 | 广州环亚化妆品科技有限公司 | 一种天然植物来源的长效保湿乳液面膜组合物及其制备方法 |
| CN107007509A (zh) * | 2017-05-19 | 2017-08-04 | 广州蜜妆生物科技有限公司 | 一种平衡修护面霜 |
| CN107811889A (zh) * | 2017-11-06 | 2018-03-20 | 诺斯贝尔化妆品股份有限公司 | 一种具有热感的无矿油暖手霜 |
Non-Patent Citations (2)
| Title |
|---|
| HAN55674299: "鸸鹋油病例", 《百度文库》 * |
| 阿迦妮化妆品专卖店: "阿迦妮-修护还原膏", 《HTTP://WWW.ZHUANGXUAN.CN/ZMD/AJIANI/PRO/1083.HTML》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109568329A (zh) * | 2018-12-07 | 2019-04-05 | 中国人民解放军第二军医大学 | 甘草酸及其药学上可接受的盐在制备抗抑郁药物中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105769654B (zh) | 一种舒敏护肤组合物及其在化妆品中的应用 | |
| CN109288764B (zh) | 一种纯露喷雾及其制备方法 | |
| CN108186394A (zh) | 一种舒敏修护滋养面膜精华及制备方法 | |
| CN103393916A (zh) | 一种治疗皮炎的外用药膏及制备方法 | |
| CN109498523A (zh) | 一种防皲裂护肤品及其制备 | |
| CN109044941B (zh) | 一种皮肤紧致滋养保湿组合物及其制备方法和应用 | |
| CN108685755A (zh) | Ve眼部养护膏 | |
| CN106333909B (zh) | 一种淡化面部红血丝修复肌肤的乳液及其制备方法 | |
| CN106377449A (zh) | 亚麻籽油锁水紧致面膜及其制备工艺 | |
| CN104688656A (zh) | 一种美白去皱的中药面膜 | |
| CN108714207A (zh) | 益气通络膏 | |
| CN103536890B (zh) | 一种防脱生发药剂及其制备方法 | |
| CN108815111A (zh) | 一种中药祛斑美白修复组合物及其制备方法 | |
| CN107468594A (zh) | 一种肩颈疏通的植物按摩精华及制备方法 | |
| CN106511249A (zh) | 一种植物保湿美白面膜 | |
| CN105213285A (zh) | 一种祛痘洗面奶及其制备方法 | |
| CN111040896A (zh) | 一种抗菌消炎美肤手工皂 | |
| CN109439473B (zh) | 一种祛斑美容皂及其制备方法 | |
| CN105031062A (zh) | 一种祛斑药水 | |
| CN106726737A (zh) | 一种用于经络刮痧的精油组合 | |
| CN112007101A (zh) | 丁香抑菌液 | |
| CN110051604A (zh) | 藏药面膜及其制作方法 | |
| CN103028101A (zh) | 一种治疗痤疮的药水及其制备方法 | |
| CN108929811A (zh) | 一种艾草手工皂 | |
| CN108785631A (zh) | 一种陈姜保健按摩油及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181030 |
|
| RJ01 | Rejection of invention patent application after publication |